By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


 

Proneuron Biotechnologies Ltd. (Israel - Headquarters) 

P.O. Box 277

Ness-Ziona    74101  Israel
Phone: 972-8-9409550 Fax: 972-8-9409560


SEARCH JOBS


Industry
Biotechnology


Collaborations

Weizmann Institute of Science  Rehovot, Israel - Research and Development

Sheba Medical Center  Tel Hashomer, Israel - Clinical Trials, Research and Development

Rabin Medical Center (Beilinson Hospital)  Petach Tikva, Israel - Clinical Trials

Erasme Hospital  Brussels, Belgium - Clinical Trials





Company News
Proneuron Biotechnologies, Inc.'s ProCord Granted European Patent10/19/2005 5:13:06 PM
Proneuron Biotechnologies, Inc. (US Branch) Announces Milestone Patent For Copolymer-1 -- Cop-1; Patent Expands Use Of Cop-1, Previously Approved For The Treatment Of MS10/19/2005 5:12:44 PM
Proneuron Biotechnologies, Inc. (US Branch)'s Phase II Experimental ProCord Procedure For Complete Spinal Cord Injury Now Available At The Mount Sinai Medical Center In NY & University Hospital In Collaboration With Kessler Institute For Rehabilitation In NJ10/19/2005 5:12:23 PM
Shriners Hospitals For Children, Philadelphia Now Enrolling For Proneuron Biotechnologies, Inc. (US Branch)'s Phase II ProCord Study10/19/2005 5:12:14 PM
The Mount Sinai Medical Center And Kessler Institute For Rehabilitation Are Now Enrolling For Proneuron's Phase II Study Of ProCord For Neurologically Complete Spinal Cord Injury10/19/2005 5:11:40 PM
Proneuron Biotechnologies, Inc. (US Branch) And Cell Design Of Atlanta To Establish A New Cell Processing Facility In Atlanta To Support The Current Phase II Trial Of ProCord For Complete Spinal Cord Injury10/19/2005 5:11:37 PM
Shepherd Center And Proneuron Biotechnologies, Inc. (US Branch) Receive $3.2 Million Commitment From The For Phase II Study Of ProCord, An Experimental Procedure For Acute Spinal Cord Injury10/19/2005 5:10:21 PM
Proneuron Biotechnologies, Inc. (US Branch) Welcomes Dr. Marca L. Sipski To The Company's ProCord Study Steering Committee Guiding The Phase II Study Of ProCord For Complete Spinal Cord Injury10/19/2005 5:10:19 PM
Proneuron Biotechnologies Ltd. (Israel)'s ProCord Receives FDA Orphan Drug Designation10/19/2005 5:10:08 PM
Victory Found In Journey: Pool Accident Leads Lifeguard To Unproven Therapy, Change In Outlook On Life10/19/2005 5:09:21 PM
12
//-->